

ASX ANNOUNCEMENT 10 February 2020

Mayo Clinic launches clinical study to evaluate HeraBEAT™ Plus

Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") is pleased to advise that Mayo Clinic will initiate a clinical study to evaluate HMD's HeraBEAT Plus solution.

The HeraBEAT™ device safety and performance claims allow continuous and accurate measurement of foetal heart rate (FHR) and maternal heart rate (MHR) throughout the pregnancy.

The study will evaluate the ease of use, accuracy and medical value of using the HeraBEAT smart foetal heart rate monitor at home.

The HeraBEAT™ is a wireless Smart Foetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy.

The HeraBEAT™ device uses a smartphone-based interface, with real-time instructions for expectant mothers for determining both foetal heart rate and maternal heart rate.

This study will recruit low-risk expectant mothers from the Obstetrics and Gynecology Department at Mayo Clinic in Rochester, Minnesota. The overall study will be guided by an assessment of device functionality and user acceptability, as well as an evaluation of the impact of the device on expectant mother's perception of foetal well-being, as measured by standardized surveys.

Principal Investigator of the trial is Yvonne S Butler Tobah, M.D. and Mayo Clinic have financial interest in the technology referenced in this announcement. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

CEO and Cofounder Mr David Groberman said: "The decision to initiate a clinical study by HeraMED's R&D collaborator is a major milestone and another significant building block in HeraMED's US expansion strategy

This announcement has been approved by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited Company Secretary
CEO and Co-Founder Stephen Buckley

David Groberman T: +61 (0) 8 6189 1155

E: stephen@hera-med.com

E: david@hera-med.com

M: +972-52-6991188

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical Data and Technology company leading the digital transformation of prenatal care. HeraMED utilises the digital health ecosystem including clinical home monitoring devices, cloud computing, artificial intelligence, big data and digital social networking to reshape the Doctor/Patient relationship. The Company is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, to deliver better care at a lower cost. Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.